Rockefeller Capital Management
ATNM icon

Rockefeller Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Rockefeller Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.98K Hold
4,000
– – ﹤0.01% 4286
2025
Q4 		$5.44K Sell
4,000
-500
-11% -$729 ﹤0.01% 4046
2025
Q3 		$7.2K Buy
+4,500
New +$7.33K ﹤0.01% 3768
2023
Q3 		– Sell
-14,733
Closed -$109K – 1504
2023
Q2 		$109K Sell
14,733
-1,190
-7% -$10.1K ﹤0.01% 1767
2023
Q1 		$150K Buy
15,923
+842
+6% +$8.89K ﹤0.01% 1860
2022
Q4 		$160K Buy
15,081
+750
+5% +$7.61K ﹤0.01% 1772
2022
Q3 		$105K Buy
14,331
+1,450
+11% +$9.01K ﹤0.01% 1961
2022
Q2 		$61K Buy
12,881
+1,000
+8% +$5.68K ﹤0.01% 2191
2022
Q1 		$60K Buy
11,881
+3,500
+42% +$18.4K ﹤0.01% 2212
2021
Q4 		$50K Hold
8,381
– – ﹤0.01% 2215
2021
Q3 		$74K Buy
8,381
+1,500
+22% +$10.4K ﹤0.01% 1985
2021
Q2 		$54K Hold
6,881
– – ﹤0.01% 2037
2021
Q1 		$52K Buy
6,881
+3,101
+82% +$26.3K ﹤0.01% 1869
2020
Q4 		$29K Buy
3,780
+1,677
+80% +$18.2K ﹤0.01% 1859
2020
Q3 		$20K Buy
2,103
+922
+78% +$10.2K ﹤0.01% 1780
2020
Q2 		$12K Buy
1,181
+348
+42% +$2.64K ﹤0.01% 1830
2020
Q1 		$5K Buy
+833
New +$5.92K ﹤0.01% 1934

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's ATNM Position: Q1 2026 in Review

Rockefeller Capital Management held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 4,000 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #4286.

Rockefeller Capital Management first reported a position in ATNM in Q1 2020 and has held it in 17 quarters since. The position peaked at $160K in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Rockefeller Capital Management held 4,000 shares of Actinium Pharmaceuticals worth $3.98K as of Q1 2026.
  • Rockefeller Capital Management left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4286 holding.
  • Rockefeller Capital Management first reported a position in Actinium Pharmaceuticals in Q1 2020 and has held it in 17 quarters since.
  • Rockefeller Capital Management's Actinium Pharmaceuticals position peaked at $160K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.